Starling Oncology (STLNW) Cash & Equivalents (2019 - 2026)

Starling Oncology (STLNW) has reported Cash & Equivalents for 8 consecutive years, with $41.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash & Equivalents rose 35.66% year-over-year to $41.1 million; the trailing twelve-month figure through Jun 2026 stood at $41.1 million (up 35.66% YoY), and the FY2025 full-year result was $33.6 million, down 32.42% from the prior year.
• Cash & Equivalents improved to $41.1 million in Q2 2026 per STLNW's latest filing, from $30.3 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $95.5 million in Q1 2022 and bottomed at $14.0 million in Q4 2022.
• Historically, Cash & Equivalents has averaged $39.6 million across 5 years, with a median of $34.8 million in 2024.
• The widest YoY moves for Cash & Equivalents: up 432.65% in 2022, down 87.84% in 2022.
• Over 5 years, Cash & Equivalents stood at $14.0 million in 2022, then jumped by 139.03% to $33.5 million in 2023, then soared by 48.32% to $49.7 million in 2024, then plunged by 32.42% to $33.6 million in 2025, then gained by 22.43% to $41.1 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $41.1 million, $30.3 million, and $33.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.